Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06439082RecruitingPhase 3
Crizanlizumab for sickle cell pain crises
This trial tests whether crizanlizumab can reduce painful sickle cell crises (called vaso-occlusive crises or VOCs) in people with sickle cell disease who have frequent crises. It may be an option for those who still have crises despite current treatments.
Birmingham, AlabamaAges 12–100 - NCT06021483Recruiting
Observing safety and effectiveness of Zepzelca for lung cancer
This study tracks how safe and effective the drug Zepzelca (a chemotherapy) is for people with advanced small cell lung cancer that has not responded to earlier platinum-based chemo. It allows patients to receive the drug as part of their normal care while researchers collect data.
SeoulAges 19 years+ - NCT06411925RecruitingPhase 4
Atock Dry Syrup for children with acute bronchitis
This trial tests a new cough syrup (Atock Dry Syrup) for children with acute bronchitis. If your child has a bad cough, wheezing, and symptoms started in the last 2 days, this treatment may help ease their symptoms.
SeoulAges 6 months–11 years - NCT06414954RecruitingPhase 2
Study of an oral medication for myasthenia gravis
This trial tests an experimental oral medication called NMD670 for people with myasthenia gravis (MG). It aims to see if the drug is safe and if it helps improve muscle strength and daily function.
Carlsbad, CaliforniaAges 18 years+ - NCT06419374RecruitingPhase 3
Testing a new drug for liver scarring from MASH
This trial tests a new drug called pegozafermin to see if it can help people with cirrhosis (scarring) of the liver caused by MASH (a fatty liver disease). If you have cirrhosis and either diabetes or multiple risk factors, this study might be an option for you.
Birmingham, AlabamaAges 18–75 - NCT06410443Recruiting
Steroid treatment for radiation-induced bowel injury
This trial tests if local steroids can help heal bowel damage caused by radiation therapy for cancer. It may reduce pain, bleeding, and urgency, and improve quality of life.
Shenyang, LiaoningAges 18 years+ - NCT06397911RecruitingPhase 2
Testing FB825 for moderate to severe eczema
This trial tests a new injectable medicine called FB825 for people with moderate to severe eczema that hasn't improved enough with standard creams. The study aims to see if FB825 can reduce itching and skin symptoms safely.
Fountain Valley, CaliforniaAges 18–65 - NCT06389877RecruitingPhase 1/Phase 2
Gene therapy for adults with alpha-1 antitrypsin deficiency
This study tests a one-time gene therapy called BEAM-302 that aims to fix the faulty gene causing alpha-1 antitrypsin deficiency (AATD), a condition that damages the lungs and liver. The goal is to improve AAT levels and slow or stop disease progression.
Birmingham, AlabamaAges 18–75 - NCT06387121RecruitingPhase 2
Low-dose chemo plus immune drugs for new B-ALL
This trial tests a combination of low-dose chemotherapy and immune-targeted drugs for adults newly diagnosed with a specific type of leukemia. The goal is to find a treatment that is effective with fewer side effects.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06120166RecruitingEarly Phase 1
Metabolically armed CAR-T cells for relapsed B-cell lymphoma
This trial tests a new type of CAR-T cell therapy (Meta10-19) for people with aggressive B-cell lymphoma that has not responded to two or more standard treatments. The therapy is designed to be more powerful inside the body to attack cancer cells.
Hangzhou, ZhejiangAges 18 years+ - NCT06363760Enrolling by invitation
Long-term follow-up after EDIT-301 gene therapy
This long-term follow-up study monitors people with sickle cell disease or transfusion-dependent beta-thalassemia who have already received the gene-editing therapy EDIT-301. It helps researchers understand how safe and effective the treatment is over time.
Oakland, CaliforniaAges 12–50 - NCT06361888RecruitingPhase 2/Phase 3
Testing a new drug combo for advanced pancreatic cancer
This trial tests a combination of four drugs (surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine) as a first treatment for people whose pancreatic cancer has spread to other parts of the body. The goal is to see if this combination helps shrink tumors and improve survival.
Hefei, AnhuiAges 18–75 - NCT06359041RecruitingPhase 1/Phase 2
CABA-201 cell therapy for generalized myasthenia gravis
This trial tests a new cell therapy called CABA-201 for people with generalized myasthenia gravis. It aims to reset the immune system to reduce muscle weakness and improve daily functioning.
Orange, CaliforniaAges 18–70 - NCT06351631RecruitingPhase 3
Long-term safety study of bomedemstat for blood cancers
This trial checks the long-term safety and continued benefits of bomedemstat for people with certain blood cancers (like essential thrombocythemia and polycythemia vera) who have already been doing well on the drug in an earlier study.
Ann Arbor, MichiganAges 18 years+ - NCT06343298RecruitingPhase 2
Study of manp for hard-to-control high blood pressure
This study tests a new investigational drug called MANP to see if it can lower blood pressure in people whose blood pressure stays high even when they are already taking several medications. If it works, this drug might offer a new option for people with difficult-to-control hypertension.
Little Rock, ArkansasAges 18–80 - NCT06353386RecruitingPhase 1/Phase 2
Opevesostat combinations for advanced prostate cancer
This study tests a new drug called opevesostat, alone or combined with other treatments, for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It aims to see if it can help control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06358209Recruiting
Washing the brain for infection treatment
This study tests whether washing out the infected fluid spaces in the brain (ventricular irrigation) can safely treat a serious brain infection (ventriculitis). It is for adults with a confirmed infection and fever who are stable enough for the procedure.
Hefei, AnhuiAges 18–65 - NCT06352008RecruitingPhase 2
Anlotinib for lung cancer patients with incomplete response after chemo-immunotherapy
This trial tests if anlotinib (a targeted therapy) can help prevent lung cancer from returning after surgery for patients whose tumors did not completely disappear after chemotherapy plus immunotherapy before surgery.
TianjinAges 18 years+ - NCT06348134RecruitingPhase 2
Anti-HER2 Therapy Before and After Surgery for HER2-Positive Breast Cancer
This trial tests a targeted therapy (anti-HER2) given before and after surgery for Nigerian women with HER2-positive breast cancer. It aims to see if this treatment helps shrink tumors and improve outcomes.
Ikeja, LagosAges 18 years+ - NCT06352645Recruiting
Testing a compact water flosser for gum health
This trial tests a new water flosser (Bixdo Ultra Compact) to see if it safely improves gum health in people with moderate to severe gum disease. You would use the flosser at home and attend check-ups for about 4 weeks.
Boston, MassachusettsAges 18–70 - NCT06336044Recruiting
Facial filler trial with hyaluronic acid and collagen
This trial tests a new injectable filler made from hyaluronic acid and recombinant collagen to smooth wrinkles and add volume. It may help people who want a non-surgical option for facial rejuvenation.
RomaAges 18–70 - NCT06318169RecruitingPhase 3
Testing pegozafermin for MASH and liver fibrosis
This trial tests an experimental drug called pegozafermin to see if it can help people with MASH (a fatty liver disease) and liver scarring (fibrosis). It's for people who have moderate-to-advanced scarring but not cirrhosis, and who have not had other serious liver conditions or poorly controlled diabetes.
Birmingham, AlabamaAges 18–80 - NCT06328777RecruitingPhase 2/Phase 3
Testing a new immune cell therapy for systemic sclerosis (scleroderma)
This trial tests a new treatment called CABA-201, which uses your own immune cells to target and calm the overactive immune system causing scleroderma. It aims to reduce symptoms and slow or stop the disease's progression.
New Haven, ConnecticutAges 18–75 - NCT06323213RecruitingPhase 3
Testing a new asthma medicine for severe asthma
This study tests an experimental drug called 610 for people with severe asthma that is not well-controlled with standard medicines. The goal is to see if adding 610 can improve asthma control and reduce flare-ups.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.